Armistice Capital LLC acquired a new position in shares of Vincerx Pharma, Inc. (NASDAQ:VINC – Free Report) during the 2nd quarter, HoldingsChannel.com reports. The institutional investor acquired 1,988,000 shares of the company’s stock, valued at approximately $1,610,000. Armistice Capital LLC owned approximately 0.07% of Vincerx Pharma as of its most recent filing with the Securities and Exchange Commission (SEC).
Separately, Marshall Wace LLP increased its position in shares of Vincerx Pharma by 359.1% during the second quarter. Marshall Wace LLP now owns 328,533 shares of the company’s stock worth $266,000 after acquiring an additional 256,967 shares in the last quarter. Institutional investors and hedge funds own 44.02% of the company’s stock.
Vincerx Pharma Stock Performance
Shares of NASDAQ VINC opened at $0.70 on Friday. The stock has a market cap of $20.77 million, a price-to-earnings ratio of -0.39 and a beta of 1.51. Vincerx Pharma, Inc. has a fifty-two week low of $0.51 and a fifty-two week high of $9.37. The firm’s 50-day simple moving average is $0.68 and its 200 day simple moving average is $1.47.
About Vincerx Pharma
Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.
Featured Articles
- Five stocks we like better than Vincerx Pharma
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Rocket Lab Stock Soars: Should Investors Chase the Rally?
- Do ETFs Pay Dividends? What You Need to Know
- KB Home Slips After Earnings: What’s Next for Homebuilders?
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Micron Stock Soars as AI Demand Fuels Big Q4 Earnings Beat
Want to see what other hedge funds are holding VINC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vincerx Pharma, Inc. (NASDAQ:VINC – Free Report).
Receive News & Ratings for Vincerx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vincerx Pharma and related companies with MarketBeat.com's FREE daily email newsletter.